UK markets close in 3 hours 28 minutes
  • FTSE 100

    7,485.66
    +19.75 (+0.26%)
     
  • FTSE 250

    20,286.89
    +41.46 (+0.20%)
     
  • AIM

    929.34
    +0.98 (+0.11%)
     
  • GBP/EUR

    1.1800
    -0.0018 (-0.15%)
     
  • GBP/USD

    1.2133
    -0.0069 (-0.57%)
     
  • BTC-GBP

    19,535.64
    -826.79 (-4.06%)
     
  • CMC Crypto 200

    562.76
    -11.98 (-2.08%)
     
  • S&P 500

    4,207.27
    -2.97 (-0.07%)
     
  • DOW

    33,336.67
    +27.16 (+0.08%)
     
  • CRUDE OIL

    92.89
    -1.45 (-1.54%)
     
  • GOLD FUTURES

    1,801.00
    -6.20 (-0.34%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • HANG SENG

    20,175.62
    +93.19 (+0.46%)
     
  • DAX

    13,755.19
    +60.68 (+0.44%)
     
  • CAC 40

    6,555.32
    +10.65 (+0.16%)
     

Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™

In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Immunocore Holdings Limited
Immunocore Holdings Limited
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting